首页 | 本学科首页   官方微博 | 高级检索  
检索        

VEGF信号通路抑制剂相关蛋白尿的研究进展
引用本文:马兴群,成远.VEGF信号通路抑制剂相关蛋白尿的研究进展[J].临床肿瘤学杂志,2015,20(4):357-362.
作者姓名:马兴群  成远
作者单位:210002.南京 解放军八一医院全军肿瘤中心
基金项目:南京军区重点课题基金项目(14ZD21)
摘    要:血管内皮生长因子(VEGF)信号轴在建立和维持肾小球滤过屏障中发挥不可或缺的作用。蛋白尿是VEGF信号通路抑制剂的常见不良反应之一,该类药物可引起肾小球足细胞和肾小球毛细血管内皮细胞损伤,甚至导致血栓性微血管病变。目前临床也缺乏针对性的治疗方案。本文就该类药物相关性蛋白尿的发生现状、发病的可能机制及治疗 方法 作一综述。

关 键 词:血管内皮生长因子  蛋白尿  足细胞  贝伐珠单抗
收稿时间:2014-06-26
修稿时间:2014-11-04

Research progress of proteinuria associated with vascular endothelial growth factor inhibitors
MA Xingqun , CHENG Yuan , CHEN Yingxia.Research progress of proteinuria associated with vascular endothelial growth factor inhibitors[J].Chinese Clinical Oncology,2015,20(4):357-362.
Authors:MA Xingqun  CHENG Yuan  CHEN Yingxia
Institution:Cancer Center, 81 Hospital of PLA, Nanjing 210002,China
Abstract:Vascular endothelial growth factor signalling pathway is indispensable for the normal development and maintenance of glomerular filtration barrier. Proteinuria is shared toxic effect among all the vascular endothelial growth factor inhibitors, which may result in podocyte cell injury, glomerular endothelial cell injury, even renal thrombotic microangiopathy. The mechanisms of proteinuria secondary to vascular endothelial growth factor inhibitors were not well interpreted, and now no specific recommendation for antiproteinuric agent can be available. We review the mechanisms, incidence and managements for proteinuria associated with vascular endothelial growth factor inhibitors.
Keywords:Vascular endothelial growth factor( VEGF)  Proteinuria  Potocyte  Bevacizumab
本文献已被 CNKI 万方数据 等数据库收录!
点击此处可从《临床肿瘤学杂志》浏览原始摘要信息
点击此处可从《临床肿瘤学杂志》下载免费的PDF全文
设为首页 | 免责声明 | 关于勤云 | 加入收藏

Copyright©北京勤云科技发展有限公司  京ICP备09084417号